RecruitingPhase 3NCT06533098
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Studying Fetal and neonatal alloimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- Nipocalimab(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18-45 years · FEMALE
- Timeline
- 2025 – 2029
Study locations (22)
- The University of Alabama at Birmingham, Birmingham, Alabama, United States
- UC Davis School of Medicine, Sacramento, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- Advocate Children's Hospital, Park Ridge, Illinois, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Texas Medical Branch, Galveston, Texas, United States
- Medizinische Universitaet Graz, Graz, Austria
- Medical University Vienna, Vienna, Austria
- Universitaetsklinikum Giessen und Marburg GmbH, Giessen, Germany
- Medizinische Hochschule Hannover, Hanover, Germany
- Universitatsklinikum Jena, Jena, Germany
- Universitaetsklinikum Tuebingen, Tübingen, Germany
- Leiden University Medical Center, Leiden, Netherlands
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06533098 on ClinicalTrials.govOther trials for Fetal and neonatal alloimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06449651A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)Janssen Research & Development, LLC
- RECRUITINGNCT04598750The Neonatal Hemorrhagic Risk Assessment in ThrombocytopeniaKarolinska Institutet
See all trials for Fetal and neonatal alloimmune thrombocytopenia →